Validation of two spectrophotometric methods for fluoxetine quantification


  • Gaspar Joana Instituto Politécnico de Coimbra, ESTESC-Coimbra Health School, Farmácia, Portugal
  • Barbosa ZÉlia


Objective: This paper describes the development and validation of two UV-Visible spectrophotometric analysis methods, using absolute ethanol (method A) and HCl 0.1 M (method B) as solvents, to quantify fluoxetine (FLX) in its generic and brand name form. The objective is to validate both methods and compare the concentrations of the samples obtained from each one.

Methods: Validation of each method with the determination of linearity, limit of detection and quantification, intermediary precision, robustness, accuracy and uniformity of mass for both samples was performed.

Results: Uniform distribution of FLX in capsules were verified and good linear relationships were found between the readings and the concentrations of FLX, in the ranges of 100 µg/ml to 300 µg/ml and 5 µg/ml to 25 µg/ml, for method A and B, respectively. The limit of quantification obtained was 9.96 µg/ml for method A and 0.87 µg/ml for method B. The limit of detection obtained was 2.988 µg/ml for method A and 0.26 µg/ml for method B. Was also verified robustness, good inter-day precision and accuracy of both methods.

Conclusion: The methods were successfully validated to the determination of FLX in its pharmaceutical formulations.

Keywords: Fluoxetine, UV-Visible spectrophotometry, Quantification, Validation


Download data is not yet available.


Lencastre RP, Matos CD, Garrido J, Borges F, Garrido EM. Voltammetric quantification of fluoxetine: application to quality control and quality assurance processes. J Food Drug Anal 2006;14:242–6.

Omar MA, Abdelmageed OH, Derayea SM, Attia TZ. Spectrofluorimetric protocol for antidepressant drugs in dosage forms and human plasma through derivatization with dansyl chloride. Arab J Chem 2013. doi:10.1016/j.arabjc.2013.12.015. [Article in Press]

Sabbioni C, Bugamelli F, Varani G, Mercolini L, Musenga A, Saracino MA, et al. A rapid HPLC-DAD method for the analysis of fluoxetine and norfluoxetine in plasma from overdose patients. J Pharm Biomed Anal 2004;36:351–6.

Alizadeh R, Najafi NM, Poursani EMA. Arrays of SnO2 nanorods as novel solid phase microextraction for trace analysis of antidepressant drugs in body fluids. J Pharm Biomed Anal 2012;70:492–8.

Flores JR, Nevado JJB, Peñalvo GC, Diez NM. Development and validation method for determination of fluoxetine and its main metabolite norfluoxetine by nonaqueous capillary electrophoresis in human urine. Talanta 2005;65:163–71.

Sartori ER, Suarez WT, Fatibello-Filho O. Conductometric determination of fluoxetine hydrochloride in pharmaceutical formulations. Anal Lett 2009;42:659–67.

Murakami JN, Thurbide KB, Lambertus G, Jensen E. Characterization of the subcritical water extraction of fluoxetine hydrochloride. J Chromatogr A 2012;1250:80–4.

Brenna E, Fronza G, Fuganti C. Traceability of synthetic drugs by position-specific deuterium isotope ratio analysis: the case of prozac and the fluoxetine generics. Anal Chim Acta 2007;601:234–9.

An MA, Manea F, Pode R. Electrochemical detection of fluoxetine using a boron-doped diamond electrode. Int J Pharm Pharm Sci 2013;5:318–22.

Moura, Jacira Izidório, Moita GC. Simultaneous determination of olanzapine and fluoxetine hydrochloride in pharmaceutical formulations by derivative spectrophotometry. Quim Nova 2012;35:627–33.

Nazario CED, Gomes PCFL, Lancas FM. Analysis of fluoxetine and norfluoxetine in human plasma by HPLC-UV using a high purity C18 silica-based SPE sorbent. Anal Methods 2014;6:4181.

Oliveira AFF, Figueiredo EC, Santos-Neto AJ. Analysis of fluoxetine and norfluoxetine in human plasma by liquid-phase microextraction and injection port derivatization GC-MS. J Pharm Biomed Anal 2013;73:53–8.

Freitas DF, Porto CED, Vieira EP, Siqueira MEPB. Three-phase, liquid-phase microextraction combined with high-performance liquid chromatography-fluorescence detection for the simultaneous determination of fluoxetine and norfluoxetine in human plasma. J Pharm Biomed Anal 2010;51:170–7.

Darwish IA, Amer SM, Abdine HH, Al-Rayes LI. New spectrophotometric and fluorimetric methods for determination of fluoxetine in pharmaceutical formulations. Int J Anal Chem 2009:257-306. [Article in Press]

Shah J, Jan MR, Khan MN, Durrani S. Quantitative determination of fluoxetine in pharmaceuticals and plasma samples using bromatometric method. Am J Anal Chem 2012;3:828–35.

Fkhami AA, Adrakian TM, Halafi LK. Spectrophotometric determination of fluoxetine by batch and flow injection methods. Chem Pharm Bull 2006;54:1642–6.

Amin AS, Ahmed IS, Dessouki HA, Mohamed HA. Spectrophotometric quantification of fluoxetine hydrochloride: Application to quality control and quality assurance processes. Chem Papers 2010;64:278–84.

Papoutsis I, Khraiwesh A, Nikolaou P, Pistos C, Spiliopoulou C, Athanaselis S. A fully validated method for the simultaneous determination of 11 antidepressant drugs in whole blood by gas chromatography-mass spectrometry. J Pharm Biomed Anal 2012;70:557–62.

Suarez WT, Sartori ER, Ferreira É. Flow-injection turbidimetric determination of fluoxetine hydrochloride in pharmaceutical formulations. Quim Nova 2009;32:2396–400.

Nevado JJB, Llerena MJV, Salcedo a MC, Nuevo EA. Assay validation for three antidepressants in pharmaceutical formulations: practical approach using capillary gas chromatography. J Pharm Biomed Anal 2005;38:52–9.

Marques KL, Santos JLM, Lima JLFC. Application of pulsed flow analysis for chemiluminescent screening of counterfeit fluoxetine pharmaceuticals. Anal Lett 2007;40:2241–51.

Omar MA, Abdelmageed OH, Derayea SM, Uno T, Atia TZ. Spectrofluorimetric determination of certain antidepressant drugs in human plasma. J Anal Sci Technol 2013;4:5.

Darwish IA. Development and validation of spectrophotometric methods for determination of fluoxetine, sertraline, and paroxetine in pharmaceutical dosage forms. J AOAC Int 2005;88:1–8.

McLay R, Klinski A. Changes in prescription habits with the introduction of generic fluoxetine. Mil Med 2008;173:100–4.

Druss BG, Marcus SC, Olfson M, Pincus HA. Listening to generic prozac: winners, losers, and sideliners. Health Aff (Millwood) 2004;23:210–6.

Italiano D, Spina E. Generic antidepressant drugs: a reappraisal. J Psychopathol 2013;3:19.

Shields BJ, Nahata MC. Efficacy of brand name vs. generic fluoxetine. Perspect Psychiatr Care 2003;39:122.

Yu BP, Chong YS, Maguire GA. Is generic fluoxetine effective? J Affective Disord 2004;81:185–6.

European Medicines Agency. Guideline of the investigation of bioequivalence. London; 2010. p. 1–27.

Fregonezi-nery MM, Baracat MM, Casagrande R, Machado HT, Miglioranza B, Gianotto EA dos S, et al. Validation of methods for determination of fluoxetine capsules. Quim Nova 2008;31:1665–9.

Agência Nacional de Vigilância Sanitária. Farmacopeia Brasileira. Atheneu. 4th ed. São Paulo; 2005. p. 101.

Andrade DF, Carvalho JS, Freitas MB. Qualidade de cápsulas de fluoxetina disponibilizadas pelo sistema único de saúde: estudo in vitro das condições do ensaio de dissolução. J Basic Appl Pharm Sci 2013;34:199–205.

Anfarmag. 2nd ed. Manual de Equivalência; 2006. p. 8.

Raggi M, Bugamelli F, Casamenti G, Mandrioli R, De Ronchi D, Volterra V. Analytical methods for the quality control of Prozac® capsules. J Pharm Biomed Anal 1998;18:699–706.

ICH. International Conference on Harmonization of Technical Requirements for Registration on Pharmaceuticals for Human Use Q2(R1). Validation of Analytical Procedures; 2005.

Anvisa. Resolução RE no899; 2003. p. 1–15.

Miller JN, Miller JC. Statistics and chemometrics for analytical chemistry. 6th ed. Pearson Education Limited; 2010.

Ministério da Saúde I. Farmacopeia portuguesa. 8th ed. Lisboa; 2005. p. 242.

The United States Pharmacopeial Convention. United States Pharmacopeia National Formulary (USP32NF27), The Official Compendia of Standards. 29th ed. Rockville; 2009.



How to Cite

Joana, G., and B. ZÉlia. “Validation of Two Spectrophotometric Methods for Fluoxetine Quantification”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 3, Mar. 2016, pp. 72-78,



Original Article(s)